← All trials
NCT04968366
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2021
- Primary completion
- Aug 31, 2022
- Completion date
- Aug 31, 2024
- First posted
- Jul 20, 2021
- Last posted
- Jul 20, 2021
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityReponsible party - principal investigator
- Capital Medical UniversityOverall official - principal investigator
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.